FLAG Therapeutics is developing cancer therapeutics using new classes of small molecules having selective dual activity: antiangiogenesis and chemotherapeutic: two investigational product platforms--the Anti-angiogenic/Anti-tubulin (AA/AT) platform and Folate-target Anti-cancer (FTAC) platform.An area of focus is LAG-003, a small molecule which has anti-angiogenic and anti-tubulin properties for the treatment of Glioblastoma brain tumors. FLAG has licensed two classes of small molecules from Duquesne University (Pgh, PA): AA/AT compounds which are both anti-angiogenic and antitubulin; and FTAC compounds, which are cytotoxic but only taken up by a novel receptor that only sits on certain cancer cells.
